Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate an intravenous (by injection) investigational
medication to treat Crohn's disease in patients with at least one perianal fistula. The
research is being conducted at up to 5 clinical research sites in the US and Europe and is
open to both men and women ages 18 to 70 years old. Participants in the study will have a
number of visits to a research site over a 17 month period. All study-related care and
medication is provided to qualified participants at no cost: this includes all visits,
examinations and laboratory work.
Visilizumab is a humanized antibody (antibodies are proteins that are normally made by the
immune system to help defend the body from infections and other foreign substances) that is
directed against T cells. Visilizumab selectively attacks problematic T cells and, in doing
so, it may prevent them from causing inflammation. Visilizumab has also been observed to have
a suppressive effect on the body's immune system (system in the body that reacts to foreign
or occasionally one's own proteins).